These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 19057167)
21. Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnestic MCI. Salloway S; Correia S; Richardson S Int Psychogeriatr; 2008 Feb; 20(1):40-6. PubMed ID: 17597552 [TBL] [Abstract][Full Text] [Related]
22. The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Doraiswamy PM; Kaiser L; Bieber F; Garman RL Alzheimer Dis Assoc Disord; 2001; 15(4):174-83. PubMed ID: 11723368 [TBL] [Abstract][Full Text] [Related]
23. Overview of methodologic issues for pharmacologic trials in mild, moderate, and severe Alzheimer's disease. Reisberg B; Franssen EH; Bobinski M; Auer S; Monteiro I; Boksay I; Wegiel J; Shulman E; Steinberg G; Souren LE; Kluger A; Torossian C; Sinaiko E; Wisniewski HM; Ferris SH Int Psychogeriatr; 1996; 8(2):159-93. PubMed ID: 8994889 [TBL] [Abstract][Full Text] [Related]
24. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy. Wattmo C; Minthon L; Wallin ÅK Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213 [TBL] [Abstract][Full Text] [Related]
25. Behavioral manifestations of dementia: a research agenda. Tariot PN Int Psychogeriatr; 1996; 8 Suppl 1():31-8. PubMed ID: 8934263 [No Abstract] [Full Text] [Related]
26. Time to Treatment Initiation in People With Alzheimer Disease: A Meta-Analysis of Randomized Controlled Trials. Tsoi KK; Hirai HW; Chan JY; Kwok TC J Am Med Dir Assoc; 2016 Jan; 17(1):24-30. PubMed ID: 26392193 [TBL] [Abstract][Full Text] [Related]
28. Clinical global impressions in Alzheimer's clinical trials. Schneider LS; Olin JT Int Psychogeriatr; 1996; 8(2):277-88; discussion 288-90. PubMed ID: 8994897 [TBL] [Abstract][Full Text] [Related]
29. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials. Cedarbaum JM; Jaros M; Hernandez C; Coley N; Andrieu S; Grundman M; Vellas B; Alzheimers Dement; 2013 Feb; 9(1 Suppl):S45-55. PubMed ID: 22658286 [TBL] [Abstract][Full Text] [Related]
30. ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Cummings JL; Cohen S; van Dyck CH; Brody M; Curtis C; Cho W; Ward M; Friesenhahn M; Rabe C; Brunstein F; Quartino A; Honigberg LA; Fuji RN; Clayton D; Mortensen D; Ho C; Paul R Neurology; 2018 May; 90(21):e1889-e1897. PubMed ID: 29695589 [TBL] [Abstract][Full Text] [Related]
31. Changes in neuropsychiatric symptoms as outcome measures in clinical trials with cholinergic therapies for Alzheimer disease. Cummings JL Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S1-9. PubMed ID: 9339266 [TBL] [Abstract][Full Text] [Related]
32. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials? Cortes F; Portet F; Touchon J; Vellas B J Nutr Health Aging; 2007; 11(4):330-7. PubMed ID: 17653493 [TBL] [Abstract][Full Text] [Related]
33. Clinical trials in Alzheimer's disease. A report from the Medical Research Council Alzheimer's Disease Clinical Trials Committee. Swash M; Brooks DN; Day NE; Frith CD; Levy R; Warlow CP J Neurol Neurosurg Psychiatry; 1991 Feb; 54(2):178-81. PubMed ID: 1843446 [TBL] [Abstract][Full Text] [Related]
35. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598 [TBL] [Abstract][Full Text] [Related]
36. A neuropsychological test battery for use in Alzheimer disease clinical trials. Harrison J; Minassian SL; Jenkins L; Black RS; Koller M; Grundman M Arch Neurol; 2007 Sep; 64(9):1323-9. PubMed ID: 17846273 [TBL] [Abstract][Full Text] [Related]
37. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial. Wang T; Huang Q; Reiman EM; Chen K; Li X; Li G; Lin Z; Li C; Xiao S J Clin Psychopharmacol; 2013 Oct; 33(5):636-42. PubMed ID: 23948786 [TBL] [Abstract][Full Text] [Related]
38. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Raskind MA; Peskind ER; Truyen L; Kershaw P; Damaraju CV Arch Neurol; 2004 Feb; 61(2):252-6. PubMed ID: 14967774 [TBL] [Abstract][Full Text] [Related]
39. Clinical issues of cognitive enhancers in Alzheimer disease. Calvani M; Carta A Alzheimer Dis Assoc Disord; 1991; 5 Suppl 1():S25-31. PubMed ID: 1781971 [TBL] [Abstract][Full Text] [Related]
40. Clinical drug trials in Alzheimer disease. What are some of the issues? Jarvik LF; Berg L; Bartus R; Heston L; Leith N; Phelps C; Shader R; Whitehouse P Alzheimer Dis Assoc Disord; 1990; 4(4):193-202. PubMed ID: 2264978 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]